Navigation Links
Is Aricept, the Alzheimer’s Drug Safe to Use against Vascular Dementia

Eisai is the company which markets Aricept with Pfizer Inc. Aricept is already approved in most markets to treat mild to moderate Alzheimer's disease //, but at present it was being tested in patients with vascular dementia, the second most common form of dementia after Alzheimer's disease.

But the shocking results show that about eleven patients have died while taking Aricept during a clinical trial held at Japan's Eisai Co.

There were no deaths among patients who were taking a placebo. This news would lead to calls for greater scrutiny of clinical trials.

David Windley, an analyst at Jefferies quoted that the deaths were among 648 patients who received Aricept once daily for 24 weeks. There were no deaths in the 326 patients receiving placebos.

The Eisai trial is a Phase 3 study, the final period of testing before companies present proposals to regulators for approval. Sam Gandy, chairman of medical and scientific advisory council of the Alzheimer's Association, said that it was a rather surprising result but the findings cannot negate 10 years of the drug's safety record on the market.

Gandy, who is also director of the neuroscience institute at Thomas Jefferson University in Philadelphia, said that patients taking Aricept in the latest trial showed a statistically significant improvement in cognitive function, compared with those taking placebos.

On the other hand the drug is approved for vascular dementia in a number of smaller markets, including South Korea and India.


'"/>




Page: 1

Related medicine news :

1. Miracle cure for Alzheimer’s around the corner
2. Vaccine for Alzheimer’s diseas
3. High Cholesterol linked to Alzheimer’s diseas
4. Further support for use of statins in Alzheimer’s disease
5. Catching Alzheimer’s Disease Earl
6. Alzheimer’s Continues to Ris
7. Midlife Brain Activity a Predictor Of Alzheimer’s Diseas
8. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
9. Blood Pressure An Early Warning Sign Of Alzheimer’s Disease
10. Delaying The Progression Of Alzheimer’s Disease
11. Hope For Patient With Alzheimer’s Diseas
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: